

CORPORATE PROFILE


AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products as well as alternative sources of energy. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe to be setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living, all while respecting the environment.

5 Rockefeller Plaza
20th Floor
New York, NY 10111
Phone: (212) 751-0001
<http://www.aximbiotech.com>
Info@aximbiotech.com

Grayling
101 Avenue of the Americas
8th Floor
New York, NY 10013
(646) 284 9474
shiwei.yin@grayling.com
lucia.domville@grayling.com

STOCK PERFORMANCE

Symbol	AXIM
Exchange	OTCQB
Market Cap.	248.56m
52 Week Range	4.20 - 16.245
Close	4.335
Volume	23
Shares Outstanding	56,490,271
As of Mar 23, 2018 6:15 pm	



MANAGEMENT TEAM

Dr. George E. Anastassov – Chief Executive Officer

Dr. Philip. A. Van Damme – Chief Scientific/Medical Officer

Lekhram Changoer – Chief Technology Officer

RECENT HEADLINES

[Mar 21, 2018 - AXIM Biotech to Attend BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference in New York](#)

[Mar 19, 2018 - AXIM Biotechnologies Reports Year End 2017 Results](#)

[Feb 28, 2018 - Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules](#)

[Feb 27, 2018 - AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules](#)

[Feb 21, 2018 - CBS News Covers AXIM Biotech's Patent Filing for Controlled-Release Chewing Gum to Provide Treatment for Opioid Addiction](#)